company background image
ENTX logo

Entera Bio NasdaqCM:ENTX Stock Report

Last Price

US$1.54

Market Cap

US$54.6m

7D

1.3%

1Y

14.1%

Updated

27 Mar, 2024

Data

Company Financials +

ENTX Stock Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs.

ENTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Entera Bio Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Entera Bio
Historical stock prices
Current Share PriceUS$1.54
52 Week HighUS$1.87
52 Week LowUS$0.52
Beta1.68
1 Month Change46.67%
3 Month Change179.64%
1 Year Change14.07%
3 Year Change-59.58%
5 Year Change-62.44%
Change since IPO-75.48%

Recent News & Updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

May 31
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Feb 15
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Oct 13
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Aug 11

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Jun 10
We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Jan 21
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05
Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Entera Bio EPS misses by $0.22

Nov 19

Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis

Nov 09

Shareholder Returns

ENTXUS BiotechsUS Market
7D1.3%0.9%0.4%
1Y14.1%10.3%28.8%

Return vs Industry: ENTX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ENTX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ENTX's price volatile compared to industry and market?
ENTX volatility
ENTX Average Weekly Movement20.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ENTX's share price has been volatile over the past 3 months.

Volatility Over Time: ENTX's weekly volatility has increased from 14% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200918Miranda Toledanohttps://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency.

Entera Bio Ltd. Fundamentals Summary

How do Entera Bio's earnings and revenue compare to its market cap?
ENTX fundamental statistics
Market capUS$54.64m
Earnings (TTM)-US$8.89m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.89m
Earnings-US$8.89m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ENTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.